{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:44:23Z","timestamp":1793763863860,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      This study aimed to test the ability to visually detect the characteristic medial temporal and limbic hypometabolic pattern of limbic age-related TDP-43 encephalopathy (LATE) in\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET of patients with amnestic mild cognitive impairment (aMCI) and evaluate its prognostic value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 70 patients with aMCI who underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET, amyloid-PET, tau-PET, and structural MRI, as well as baseline and follow-up cognitive evaluation.\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET scans were analyzed visually with single-subject maps, categorized as normal, Alzheimer's disease (AD)-like, LATE-like, or other neurodegenerative diseases, while blinded from other data. Clinical and biomarker features as well as cognitive trajectories were compared between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>25 scans were classified as normal, 25 as AD-like, 12 as LATE-like, and 8 as others. Patients with AD-like patterns were younger, had lower MMSE scores, inferior-to-medial temporal metabolism ratio, and greater hippocampal atrophy and cortical tau load than subjects with normal scans. Patients with LATE-like patterns had lower MMSE scores and more hippocampal atrophy than subjects with normal scans. Patients with LATE-like patterns were significantly older, had greater inferior-to-medial temporal metabolism ratio, greater amygdalar atrophy, and lower cortical tau load than subjects with AD-like patterns. Only subjects classified as AD-like showed a faster cognitive decline than negative scans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      LATE-like hypometabolic pattern in aMCI can identify a subgroup of subjects distinct from AD and controls in terms of clinical severity, medial temporal atrophy, cortical tau load, and cognitive decline, supporting the utility of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET as a biomarker that provides inferential support for the specific detection of LATE.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07395-9","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:33:03Z","timestamp":1749771183000},"page":"5075-5084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE) 18F-FDG-PET pattern in amnestic mild cognitive impairment"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-436X","authenticated-orcid":false,"given":"Cecilia","family":"Boccalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Knappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Mathoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora Elisa","family":"Peretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ribaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca B.","family":"Pizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjing","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-698X","authenticated-orcid":false,"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"7395_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol Elsevier. 2014;13:614\u201329.","journal-title":"Lancet Neurol Elsevier"},{"key":"7395_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.24125","volume":"75","author":"A Serrano-Pozo","year":"2014","unstructured":"Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol Wiley Online Libr. 2014;75:597\u2013601.","journal-title":"Ann Neurol Wiley Online Libr"},{"key":"7395_CR3","first-page":"1503","volume-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Volume 142. Brain: Oxford University Press; 2019. pp. 1503\u201327."},{"key":"7395_CR4","doi-asserted-by":"crossref","unstructured":"Mikhailenko E, Colangelo K, Tuimala J, et al. Limbic-predominant age-related TDP-43 encephalopathy in the oldest old: a population-based study. Brain. Oxford University Press UK; Epub 2024.:awae212.","DOI":"10.1093\/brain\/awae212"},{"key":"7395_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease. Acta Neuropathol. 2014;127:811\u201324.","journal-title":"Acta Neuropathol"},{"key":"7395_CR6","first-page":"2983","volume-title":"TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Volume 139. Brain: Oxford University Press; 2016. pp. 2983\u201393."},{"key":"7395_CR7","doi-asserted-by":"crossref","unstructured":"Nelson PT, Schneider JA, Jicha GA, Duong MT, Wolk DA. When Alzheimer\u2019s is LATE: why does it matter? Ann Neurol. 2023;94:211\u201322.","DOI":"10.1002\/ana.26711"},{"key":"7395_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/brain\/awy049","volume":"141","author":"H Botha","year":"2018","unstructured":"Botha H, Mantyh WG, Murray ME, et al. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain. 2018;141:1201\u201317.","journal-title":"Brain"},{"key":"7395_CR9","doi-asserted-by":"crossref","unstructured":"Grothe MJ, Moscoso A, Silva-Rodr\u00edguez J et al. Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC. Alzheimer\u2019s Dement. 2023;19(4):1234\u201344.","DOI":"10.1002\/alz.12763"},{"key":"7395_CR10","first-page":"1447","volume":"66","author":"RC Petersen","year":"2009","unstructured":"Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol Am Med Association. 2009;66:1447\u201355.","journal-title":"Arch Neurol Am Med Association"},{"key":"7395_CR11","doi-asserted-by":"publisher","unstructured":"Guedj E, Varrone A, Boellaard R et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging [online serial]. Springer Berlin Heidelberg; Epub 2021. Accessed at: https:\/\/doi.org\/10.1007\/s00259-021-05603-w","DOI":"10.1007\/s00259-021-05603-w"},{"key":"7395_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00868807","volume":"242","author":"P Scheltens","year":"1995","unstructured":"Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol Springer. 1995;242:557\u201360.","journal-title":"J Neurol Springer"},{"key":"7395_CR13","doi-asserted-by":"crossref","unstructured":"Pizzini FB, Ribaldi F, Natale V, Scheffler M, Rossi V, Frisoni GB.\u00a0A visual scale to rate amygdalar atrophy on MRI. Eur Radiol. Epub 2024.","DOI":"10.1007\/s00330-024-11249-7"},{"key":"7395_CR14","doi-asserted-by":"publisher","unstructured":"Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. Neuroimage [online serial]. Elsevier Ltd; 2020;206:116189. Accessed at: https:\/\/doi.org\/10.1016\/j.neuroimage.2019.116189","DOI":"10.1016\/j.neuroimage.2019.116189"},{"key":"7395_CR15","doi-asserted-by":"publisher","first-page":"e940","DOI":"10.1212\/WNL.0000000000005124","volume":"90","author":"H Botha","year":"2018","unstructured":"Botha H, Mantyh WG, Graff-Radford J, et al. Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology. 2018;90:e940\u20136.","journal-title":"Neurology"},{"key":"7395_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroimage.2017.07.050","volume":"161","author":"S Mishra","year":"2017","unstructured":"Mishra S, Gordon BA, Su Y, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. NeuroImage. 2017;161:171\u20138.","journal-title":"NeuroImage"},{"key":"7395_CR17","unstructured":"Mathoux G, Boccalini C, Peretti DE et al. A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [18F] flortaucipir PET in a memory clinic cohort. Eur J Nucl Med Mol Imaging. Springer; Epub. 2024.:1\u201312."},{"key":"7395_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s Dement Elsevier. 2015;11:1\u201315.","journal-title":"Alzheimer\u2019s Dement Elsevier"},{"key":"7395_CR19","doi-asserted-by":"publisher","unstructured":"Jack CR, Wiste HJ, Weigand SD, et al.\u00a0Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimer\u2019s Dement [online serial]. Elsevier Inc.; 2017;13:205\u2013216. Accessed at: https:\/\/doi.org\/10.1016\/j.jalz.2016.08.005.","DOI":"10.1016\/j.jalz.2016.08.005"},{"key":"7395_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.nicl.2014.10.009","volume":"6","author":"D Perani","year":"2014","unstructured":"Perani D, Della Rosa PA, Cerami C, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin Elsevier B V. 2014;6:445\u201354.","journal-title":"NeuroImage Clin Elsevier B V"},{"key":"7395_CR21","doi-asserted-by":"publisher","unstructured":"Cerami C, Della Rosa PA, Magnani G, et al.\u00a0Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. NeuroImage Clin [online serial]. Elsevier B.V.; 2015;7:187\u2013194. Accessed at: https:\/\/doi.org\/10.1016\/j.nicl.2014.12.004.","DOI":"10.1016\/j.nicl.2014.12.004"},{"key":"7395_CR22","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/mds.23291","volume":"25","author":"LK Teune","year":"2010","unstructured":"Teune LK, Bartels AL, De Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395\u2013404.","journal-title":"Mov Disord"},{"key":"7395_CR23","doi-asserted-by":"publisher","first-page":"E323","DOI":"10.1212\/WNL.0000000000200573","volume":"99","author":"R Mohanty","year":"2022","unstructured":"Mohanty R, Ferreira D, Frerich S, Muehlboeck JS, Grothe MJ, Westman E. Neuropathologic features of antemortem atrophy-based subtypes of Alzheimer disease. Neurology. 2022;99:E323\u201333.","journal-title":"Neurology"},{"key":"7395_CR24","doi-asserted-by":"crossref","unstructured":"Wolk DA, Nelson PT, Apostolova L et al. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimers Dement. 2025;21(1):e14202.","DOI":"10.1093\/brain\/awaf385"},{"key":"7395_CR25","doi-asserted-by":"crossref","unstructured":"Boccalini C, Caminiti SP, Chiti A, Frisoni GB, Garibotto V, Perani D. The diagnostic and prognostic value of tau-PET in amnestic MCI with different FDG-PET subtypes. Ann Clin Transl Neurol. 11(5):1236\u201349.","DOI":"10.1002\/acn3.52039"},{"key":"7395_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnen\/nlw002","volume":"75","author":"A Elobeid","year":"2016","unstructured":"Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol. 2016;75:316\u201325.","journal-title":"J Neuropathol Exp Neurol"},{"key":"7395_CR27","doi-asserted-by":"publisher","first-page":"E142","DOI":"10.1212\/WNL.0000000000008679","volume":"94","author":"L Yu","year":"2020","unstructured":"Yu L, Boyle PA, Dawe RJ, Bennett DA, Arfanakis K, Schneider JA. Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons. Neurology. 2020;94:E142\u201352.","journal-title":"Neurology"},{"key":"7395_CR28","first-page":"435","volume":"61","author":"C Amador-Ortiz","year":"2007","unstructured":"Amador-Ortiz C, Lin W, Ahmed Z, et al. TDP\u201043 immunoreactivity in hippocampal sclerosis and Alzheimer\u2019s disease. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc Wiley Online Libr. 2007;61:435\u201345.","journal-title":"Ann Neurol Off J Am Neurol Assoc Child Neurol Soc Wiley Online Libr"},{"key":"7395_CR29","unstructured":"Nelson PT, Schmitt FA, Lin Y, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. Volume 134. Oxford University Press; 2011. pp. 1506\u201318."},{"key":"7395_CR30","first-page":"2578","volume-title":"Perforant path synaptic loss correlates with cognitive impairment and alzheimer\u2019s disease in the oldest-old","author":"JL Robinson","year":"2014","unstructured":"Robinson JL, Molina-Porcel L, Corrada MM, et al. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer\u2019s disease in the oldest-old. Volume 137. Brain: Oxford University Press; 2014. pp. 2578\u201387."},{"key":"7395_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40478-018-0531-3","volume":"6","author":"S Nag","year":"2018","unstructured":"Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer\u2019s disease. Acta Neuropathol Commun Acta Neuropathol Commun. 2018;6:33.","journal-title":"Acta Neuropathol Commun Acta Neuropathol Commun"},{"key":"7395_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41582-023-00846-7","volume":"19","author":"S Nag","year":"2023","unstructured":"Nag S, Schneider JA. Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases. Nat Rev Neurol Springer US. 2023;19:525\u201341.","journal-title":"Nat Rev Neurol Springer US"},{"key":"7395_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/bpa.12424","volume":"27","author":"KE McAleese","year":"2017","unstructured":"McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer\u2019s disease, dementia with lewy bodies and ageing. Brain Pathol. 2017;27:472\u20139.","journal-title":"Brain Pathol"},{"key":"7395_CR34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-017-1681-2","volume":"133","author":"KA Josephs","year":"2017","unstructured":"Josephs KA, Murray ME, Tosakulwong N, et al. Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol Springer. 2017;133:705\u201315.","journal-title":"Acta Neuropathol Springer"},{"key":"7395_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12264-018-0300-0","volume":"35","author":"X Zhang","year":"2019","unstructured":"Zhang X, Sun B, Wang X, et al. Phosphorylated TDP-43 staging of primary age-related tauopathy. Neurosci Bull Springer. 2019;35:183\u201392.","journal-title":"Neurosci Bull Springer"},{"key":"7395_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00401-008-0463-2","volume":"117","author":"H Fujishiro","year":"2009","unstructured":"Fujishiro H, Uchikado H, Arai T, et al. Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol Springer. 2009;117:151\u20138.","journal-title":"Acta Neuropathol Springer"},{"key":"7395_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00401-010-0702-1","volume":"120","author":"O Yokota","year":"2010","unstructured":"Yokota O, Davidson Y, Bigio EH, et al. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol Springer. 2010;120:55\u201366.","journal-title":"Acta Neuropathol Springer"},{"key":"7395_CR38","first-page":"178","volume":"21","author":"A Kertesz","year":"2015","unstructured":"Kertesz A, Finger E, Murrell J, et al. Progressive supranuclear palsy in a family with TDP-43 pathology. Neurocase Taylor Francis. 2015;21:178\u201384.","journal-title":"Neurocase Taylor Francis"},{"key":"7395_CR39","doi-asserted-by":"publisher","first-page":"E1951","DOI":"10.1212\/WNL.0000000000010454","volume":"95","author":"A Kapasi","year":"2020","unstructured":"Kapasi A, Yu L, Boyle PA, Barnes LL, Bennett DA, Schneider JA. Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging. Neurology. 2020;95:E1951\u201362.","journal-title":"Neurology"},{"key":"7395_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00401-014-1302-2","volume":"128","author":"ME Murray","year":"2014","unstructured":"Murray ME, Cannon A, Graff-Radford NR, et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol. 2014;128:411\u201321.","journal-title":"Acta Neuropathol"},{"key":"7395_CR41","first-page":"804","volume":"140","author":"PA Boyle","year":"2017","unstructured":"Boyle PA, Yang J, Yu L, et al. Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain. 2017;140:804\u201312.","journal-title":"Brain"},{"key":"7395_CR42","doi-asserted-by":"publisher","unstructured":"Duong MT, Wolk DA, Limbic-predominant age-related. TDP-43 encephalopathy: LATE-Breaking updates in clinicopathologic features and biomarkers. Curr Neurol Neurosci Rep [online serial].\u00a0Springer US; 2022;22:689\u2013698. Accessed at: https:\/\/doi.org\/10.1007\/s11910-022-01232-4.","DOI":"10.1007\/s11910-022-01232-4"},{"key":"7395_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-024-00419-8","volume":"13","author":"JI L\u00f3pez-Carbonero","year":"2024","unstructured":"L\u00f3pez-Carbonero JI, Garc\u00eda-Toledo I, Fern\u00e1ndez-Hern\u00e1ndez L, et al. In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use. Transl Neurodegener. 2024;13:1\u201320.","journal-title":"Transl Neurodegener"},{"key":"7395_CR44","doi-asserted-by":"publisher","unstructured":"Thal DR, Poesen K, Vandenberghe R, Meyer S, De. Alzheimer\u2019s disease neuropathology and its estimation with fluid and imaging biomarkers. Mol Neurodegener [online serial]. BioMed Central; Epub 2025.:1\u201331. Accessed at: https:\/\/doi.org\/10.1186\/s13024-025-00819-y","DOI":"10.1186\/s13024-025-00819-y"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07395-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07395-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07395-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:44:38Z","timestamp":1781606678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07395-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":44,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7395"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07395-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VG received research support and speaker fees through her institution from Healthcare, Siemens Healthineers, Novo Nordisk. Janssen and Novartis. GBF has received support, payment, consulting fees, or honoraria through his institution for lectures, presentations, speaker bureaus, manuscript writing, or educations events from: Biogen, Roche, Diadem, Novo Nordisk, GE Healthcare, OM Pharma, and Eisai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and the subjects\u2019 consent has been waived from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The study\u2019s protocol has been approved by our local Geneva Ethics Committee (Cantonal Research Ethics Commission, Geneva, Switzerland) (NO 2016\u201301346).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}